All In Biotech

Drug Trial Radar · NCT06587425

The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase II Study Evaluating the Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Jul 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II Study Evaluating the Efficacy and Safety of LM-302 in Combination with Candonilimab and Capecitabine for First-Line Treatment in Patients with Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Conditions

  • Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • LM-302+Candonilimab+CapecitabineDrug

    LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: Cycle 1 of each cohort. Duration of one cycle is 28 days
  2. Progression Free Survival (PFS)Time frame: From enrollment until 6 months after the last participant discontinues treatment, up to approximately 42 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.